Drugs & Targets FDA approves pembro or pembro + berahyaluronidase alfa-pmph for unresectable or metastatic TMB-H solid tumors with updated indication October 23, 2026Vol.52 No.39
Drugs & Targets FDA approves bepirovirsen, first-of-its-kind chronic hepatitis B treatment October 23, 2026Vol.52 No.39
Drugs & Targets FDA clears TumorSight Risk, an AI-powered, MRI-derived breast cancer recurrence risk assessment October 23, 2026Vol.52 No.39
Drugs & Targets FDA grants breakthrough device designation for Natera’s MCED assay October 23, 2026Vol.52 No.39
Cancer Policy FDA launches Rare Disease Framework Initiative for drug development October 16, 2026Vol.52 No.38
Cancer Policy FDA seeks nominations for the Tobacco Products Scientific Advisory Committee, announces new members October 16, 2026Vol.52 No.38
Drugs & Targets FDA approves atezolizumab + chemotherapy for stage 3 colon cancer October 16, 2026Vol.52 No.38
Drugs & Targets FDA expands Anktiva approval for BCG-unresponsive non-muscle-invasive bladder cancer to cover both papillary and CIS disease October 16, 2026Vol.52 No.38
Podcast As FDA sidesteps the question of Galleri’s clinical benefit, NCI’s Letai has “some concerns” October 14, 2026
Drugs & Targets FDA approves tucatinib + trastuzumab + pertuzumab for maintenance treatment of HER2+ breast cancer October 09, 2026Vol.52 No.37
